Cellectar Biosciences Inc Share Price Nasdaq
Equities
US15117F2039
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
05-14 | Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | 44.27M 3.49B | Capitalization | 118M 9.32B |
---|---|---|---|---|---|
Net income 2024 * | -65M -5.12B | Net income 2025 * | -32M -2.52B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.67 x |
P/E ratio 2024 * |
-1.75
x | P/E ratio 2025 * |
-4.36
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.91% |
Latest transcript on Cellectar Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
James Caruso
CEO | Chief Executive Officer | 65 | 14/06/15 |
Chad Kolean
DFI | Director of Finance/CFO | 59 | 27/05/14 |
Andrei Shustov
CTO | Chief Tech/Sci/R&D Officer | - | 14/02/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 06/04/17 |
Douglas Swirsky
CHM | Chairman | 54 | 06/04/17 |
John Neis
BRD | Director/Board Member | 68 | 31/01/08 |
1st Jan change | Capi. | |
---|---|---|
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |